Microbot Medical posts negative Q3 gross margin; revenue drops 70% from Q2 to $72,000
MBOT•Microbot Medical's third-quarter 2026 revenue fell 70% from the second quarter to $72,000, and gross margin was negative. Quarter-end cash, cash equivalents and marketable securities totaled about $62 million; the company also signed a three-year exclusive distribution agreement for LIBERTY in Israel.
1. Quarterly results
Third-quarter 2026 revenue fell 70% from the second quarter to $72,000, which the company attributed to customer reorder timing and summer seasonality. Gross margin was negative, hurt by an inventory write-down and higher production costs for units manufactured in earlier periods.
2. Cash and distribution deal
Cash, cash equivalents and marketable securities totaled approximately $62 million at quarter-end, and customer accounts increased to 12. Following Israeli regulatory approval, Microbot Medical signed a three-year exclusive distribution agreement with Medtechnica to market and sell LIBERTY in Israel.




